OverviewSuggest Edit

Spark Therapeutics is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases.

TypePublic
Founded2013
HQPhiladelphia, US
Websitesparktx.com
Employee Ratings2.4

Latest Updates

Employees (est.) (Dec 2017)213
Job Openings36
Revenue (FY, 2018)$64.7 M(+437%)
Share Price (Mar 2019)$113.6

Key People/Management at Spark Therapeutics

Jeffrey D. Marrazzo

Jeffrey D. Marrazzo

Co-Founder, President and CEO
J. Fraser Wright

J. Fraser Wright

Scientific Co-Founder and CTO
Katherine A. High

Katherine A. High

Scientific Co-Founder
Show more

Spark Therapeutics Office Locations

Spark Therapeutics has an office in Philadelphia
Philadelphia, US (HQ)
3737 Market St
Show all (1)
Report incorrect company information

Spark Therapeutics Financials and Metrics

Spark Therapeutics Revenue

Spark Therapeutics's revenue was reported to be $64.73 m in FY, 2018
USD

Revenue (FY, 2018)

64.7m

Gross profit (FY, 2018)

63.7m

Gross profit margin (FY, 2018), %

98.4%

Net income (FY, 2018)

(78.8m)

EBIT (FY, 2018)

(193.6m)

Market capitalization (15-Mar-2019)

4.3b

Closing stock price (15-Mar-2019)

113.6

Cash (31-Dec-2018)

95.2m

EV

4.3b
Spark Therapeutics's current market capitalization is $4.3 b.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

633.9k22.1m20.2m12.1m64.7m

Revenue growth, %

3380%(9%)

Cost of goods sold

1.0m

Gross profit

63.7m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

2.3m1.3m1.3m1.3m1.3m1.3m1.3m1.5m1.9m15.7m25.2m10.7m

Cost of goods sold

121.0k269.0k318.0k

Gross profit

15.6m24.9m10.4m

Gross profit Margin, %

99%99%97%
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

74.6m293.5m58.9m96.7m95.2m

Accounts Receivable

244.4k16.9m16.8m

Inventories

25.6m

Current Assets

77.4m311.6m314.6m533.2m567.1m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

234.4m223.0m212.2m275.0m225.0m90.6m27.5m36.8m146.4m127.7m201.1m161.6m

Accounts Receivable

669.4k933.1k1.3m812.8k1.2m1.0m5.9m5.0m

Inventories

5.6m12.7m20.7m

Current Assets

235.9m225.1m214.3m277.8m335.3m309.2m263.4m226.3m489.1m621.0m691.6m635.2m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(24.3m)(47.1m)(123.7m)(253.5m)(78.8m)

Depreciation and Amortization

169.8k1.7m3.6m4.9m6.9m

Inventories

(25.6m)

Accounts Payable

2.3m9.1m10.0m13.0m8.7m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(9.7m)(24.1m)(41.0m)(25.6m)(54.3m)(86.8m)(52.3m)(126.6m)(191.7m)(46.4m)33.8m(13.6m)

Depreciation and Amortization

370.6k797.2k1.2m744.1k1.7m2.6m1.0m2.2m3.5m1.5m3.1m4.8m

Inventories

(5.6m)(12.7m)(20.7m)

Accounts Payable

870.4k3.2m7.7m(1.1m)(2.0m)4.2m(2.7m)4.8m839.4k(8.4m)(8.0m)(877.0k)
USDY, 2018

EV/EBIT

-22 x

EV/CFO

-60.5 x

Financial Leverage

1.6 x
Show all financial metrics

Spark Therapeutics Operating Metrics

FY, 2016

Patents and Patent Applications

297
Show all operating metrics
Report incorrect company information

Spark Therapeutics Online and Social Media Presence

Embed Graph
Report incorrect company information

Spark Therapeutics News and Updates

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Spark Therapeutics, Inc. - ONCE

NEW YORK, March 11, 2019 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Spark Therapeutics, Inc. ("Spark Therapeutics" or the "Company")...

Thinking about buying stock in Advanced Micro Devices, General Electric, China Internet Nationwide, Spark Therapeutics or Titan Pharmaceuticals?

NEW YORK, Feb. 26, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMD, CIFS, GE, ONCE, and TTNP. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Spark Therapeutics Enters into Definitive Merger Agreement with Roche

Roche to acquire Spark Therapeutics for $114.50 per share representing a total equity value of $4.8 billion

Spark Therapeutics Reports 2018 Financial Results and Recent Business Progress

PHILADELPHIA, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced today corporate and financial results for 2018 and recent business progress.

Spark Therapeutics to Host Conference Call on Tuesday, Feb. 19 at 8:30 a.m. ET to Discuss 2018 Results and Recent Business Highlights

PHILADELPHIA, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, will host a conference call on Tuesday, Feb. 19, 2019, at 8:30 a.m. ET to discuss corporate and fina…

Spark Therapeutics Announces Presentation of Preclinical Data in Pompe Disease and CLN2 Disease at 15th Annual WORLDSymposium™

PHILADELPHIA, Jan. 31, 2019 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced today the presentation of preclinical data for SPK-3006 for Pompe disease and SPK-1001 for …
Show more
Report incorrect company information

Spark Therapeutics Blogs

Spark Therapeutics to Host Conference Call on Tuesday, Nov. 6 at 8:30 a.m. ET to Discuss Third Quarter Results and Recent Business Highlights

Spark Therapeutics to Host Conference Call on Tuesday, Nov. 6 at 8:30 a.m. ET to Discuss Third Quarter Results and Recent Business Highlights Content Import Tue, 10/30/2018 - 07:32 Spark Therapeutics to Host Conference Call on Tuesday, Nov. 6 at 8:30 a.m. ET to Discuss Third Quarter Resu…

Spark Therapeutics Launches New Initiative to Raise Awareness of the Importance of Genetic Testing for People Living with Inherited Retinal Diseases

Spark Therapeutics Launches New Initiative to Raise Awareness of the Importance of Genetic Testing for People Living with Inherited Retinal Diseases Content Import Thu, 10/25/2018 - 07:34 Spark Therapeutics Launches New Initiative to Raise Awareness of the Importance of Genetic Testing for…

Spark Therapeutics Announces New Preclinical Data for Pompe Disease Gene Therapy Candidate

Data from IND-enabling studies in three species support moving SPK-3006 into the clinic in 2019 PHILADELPHIA , Oct. 08, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today

Spark Therapeutics Frequently Asked Questions

  • When was Spark Therapeutics founded?

    Spark Therapeutics was founded in 2013.

  • Who are Spark Therapeutics key executives?

    Spark Therapeutics's key executives are Jeffrey D. Marrazzo, J. Fraser Wright and Katherine A. High.

  • How many employees does Spark Therapeutics have?

    Spark Therapeutics has 213 employees.

  • What is Spark Therapeutics revenue?

    Latest Spark Therapeutics annual revenue is $64.7 m.

  • What is Spark Therapeutics revenue per employee?

    Latest Spark Therapeutics revenue per employee is $303.9 k.

  • Who are Spark Therapeutics competitors?

    Competitors of Spark Therapeutics include Guardant Health, ImaginAb and Orgenesis.

  • Where is Spark Therapeutics headquarters?

    Spark Therapeutics headquarters is located at 3737 Market St, Philadelphia.

  • Where are Spark Therapeutics offices?

    Spark Therapeutics has an office in Philadelphia.

  • How many offices does Spark Therapeutics have?

    Spark Therapeutics has 1 office.